The Efficacy of Butylphthalide Combined with Tirofiban for Progressive Cerebral Infarction and Its Influence on Serum Il-18 and Nlrp3 Inflammasome
Objective To explore the efficacy of Butylphthalide combined with Tirofiban for progressive cerebral infarc-tion and its influence on serum interleukin-18 (IL-18) and inflammasome NOD-like receptor pyrin domain-containing protein 3 (NLRP3). Methods Clinical data of 80 patients with acute progressive cerebral infarction admitted to Suzhou Kowloon Hospital from October 2020 to October 2023 were retrospectively analyzed. Patients were divided into the reference group (n=40,Tirofiban only) and the study group (n=40,Butylphthalide combined with Tirofiban) according to treatment methods. The thera-peutic effect,neurological function,serum IL-18,NLRP3,homocysteine (Hcy),C-reactive protein (CRP),evaluation of daily liv-ing ability,and adverse reactions were compared between the two groups. Results The effective rate of treatment in the study group was higher than that in the reference group (P<0.05),while the mean National Institutes of Health Stroke Scale (NIHSS) score after treatment was lower (P<0.05). The levels of IL-18,NLRP3,Hcy,and CRP in the study group were lower than those in the reference group after treatment (P<0.05),while the scores for daily living ability were higher (P<0.05). There was no statisti-cally significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Butylphthalide combined with Tirofiban can effectively reduce serum IL-18,NLRP3,Hcy,and CRP levels in patients with progressive cerebral infarction,improve neurological function and daily living ability,and is associated with few side effects and high safety.
万方数据
维普
